The risk of Severe DIAR in Trauma Patients given HSD Eileen M. Bulger, MD Associate Professor of Surgery Co-PI Resuscitation Outcomes Consortium.

Slides:



Advertisements
Similar presentations
THE CLINICAL EFFICACY OF REPEAT BRAIN CT IN PATIENTS WITH TRAUMATIC INTRACRANIAL HAEMORRHAGE WITHIN 24 HRS AFTER BLUNT HEAD INJURY.
Advertisements

Regulatory Overview of Hydroxyethyl Starch (HES) Solutions September 6, 2012 Laurence Landow MD Medical Officer, CBER.
Colloids In Anaesthetic Practice G Ogweno Dept of Medical Physiology Kenyatta University.
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Katie Clement, MD PICU Resident Lectures 2011 Traumatic Brain Injury.
An Upward Trend in Motorcycle Crashes By Joan M. Pirrung, RN, APRN-BC, and Pamela Woods, RN, CEN, BSN, SANE-A Nursing2009, February ANCC contact.
Studies of HBOC-201 in Animal Models of Hemorrhagic Shock BPAC - 14 December 2006 John R. Hess, MD, MPH, FACP, FAAAS COL, MC, US Army (Ret) Professor Pathology.
Facon T et al. Proc ASH 2013;Abstract 2.
1 Hetastarch Administration in Patients Undergoing Open Heart Surgery in Association with Cardiopulmonary Bypass (CPB) Blood Products Advisory Committee.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Colloid versus Crystalloid in Hypovolemic Shock Controversy
Illinois EMSC1 Upon completion of this lecture, you will be better able to: n Define shock n Describe key differences between the pediatric and adult circulatory.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
The Prehospital & Transport Medicine Research Program Sunnybrook & Women’s College Health Sciences Centre.
PORTLAND RESUSCITATION OUTCOMES CONSORTIUM The Hypotensive Resuscitation versus Standard Resuscitation Study (HypoResus) Traumatic Injuries, Bleeding &
National Ski Patrol, Outdoor Emergency Care, 5th ©2012 by Pearson Education, Inc., Upper Saddle River, NJ BRADY Shock Chapter 10.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Post-Event Hypothermia Julie Swain M.D. Cardiovascular Surgeon Consultant to the FDA Circ System Devices Advisory Panel Sept 2004 DRAFT slides.
TRAUMA SYSTEM Mazen S. Zenati, M.D, MPH, Ph.D. University of Pittsburgh Department of Surgery and Epidemiology.
MUSCULOSKELETAL DISEASES National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
High Fluid Need During Cardiac Surgery: Can We Do Without HES? Philippe Van der Linden MD, PhD CHU Brugmann-HUDERF, Free University of Brussels.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Osler Journal Club Dan Munoz and Adnan Malik September 13, 2006.
Therapeutic Hypothermia in Out of Hospital Cardiac Arrest towards
Progesterone and Traumatic Brain Injury. from: Progesterone is a female hormone important for the regulation of.
Updated ACIP Recommendations for Using Hepatitis A Vaccine for Postexposure and International Travel Management Miriam J. Alter, Ph.D., MPH Infectious.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Instructor Name: Title: Unit:
Chapter 32 Shock Copyright (c) The McGraw-Hill Companies, Inc. Permission required for reproduction or display.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Trauma in the elderly 18-1 TRAUMA IN THE ELDERLY.
Chapter 23 - IV Fluids and Electrolytes Seth Christian, MD MBA Tulane University Hospital and Clinic Seth Christian, MD MBA Tulane University Hospital.
Trauma in the elderly 18-1ChapterXVIII TRAUMA IN THE ELDERLY.
Albumin Safety and Efficacy as a Resuscitative Therapy in the ICU: Are all ICU patients the same? Gary R. Haynes, M.D., Ph.D. Professor, Department of.
Hemorraghic Shock Sara Parker MD VCU Trauma Conference STICU Fellow
Age of Transfused Blood: Short-Term Mortality and Long-Term Survival after Cardiac Surgery Mark Stafford-Smith, MD, CM, FRCPC, FASE Professor of Anesthesiology.
University of Texas Southwestern Resuscitation Research Projects University of Texas Southwestern Resuscitation Research Projects.
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit The SAFE Study Investigators N Engl J Med 2004: 350:
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: A randomized control trial (JAMA. 2010;304(13):1455–64)
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
1 Prevention of Dextran-Induced Anaphylactoid Reactions (DIAR) by Hapten Inhibition Laurence Landow MD, FRCPC Medical Officer Office of Blood Research.
Top Papers in Critical Care 2013 Janna Landsperger RN, MSN, ACNP-BC.
Some colloids are more equal than others: Does our choice matter? Sibylle A. Kozek-Langenecker Evangelic Hospital Vienna
Prevention of adverse reactions to dextran Karl-Gösta Ljungström M.D., Ph.D., Associate professor, Karolinska Institute Department of Surgery Danderyd.
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
Severe Traumatic Brain Injury Scott Silvers, MD, FACEP.
1 Shock. 2 Shock refers to an abnormality of the circulatory system in which there is inadequate tissue perfusion due to a relatively or absolutely inadequate.
Safety of Albumin Revisited Blood Products Advisory Committee Meeting March 17, 2005 Laurence Landow MD, FRCPC.
Alemtuzumab BLA committee CD52 Expression Leukocytes B- lymphocytes T- lymphocytes Monocytes Macrophages Thymocytes Granulocytes (
1 INTRODUCTION: Proposed Use of HBOC-201 * in the RESUS (Restore Effective SUrvival in Shock) Trauma Trial Laurence Landow MD, FRCPC Medical Officer, Clinical.
D EPARTMENT OF N EUROSURGERY North Queensland Region Townsville- Cairns- Mackay Pre-hospital Guidelines for Neurotrauma in Rural and Remote Australia -
A pilot randomized controlled trial Registry #: NCT
Tobacco treatment TrAining Network in Crete Tobacco treatment TrAining Network in Crete.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
CONSULTANT DEPARTMENT OF ANESTHESIOLOGY RAND MEMORIAL HOSPITAL FREEPORT BAHAMAS.
Safety Review. 2 Sources of Safety Information BLA (Applicant’s data) – : Voluntary questionnaires –2008-present: SCTOD FDA Dockets Literature.
Mohit Bhandari, MSc, MD, FRCSC Associate Professor, McMaster University, Hamilton, Ontario Femoral Nailing: Reamed vs. Unreamed.
Neurological Emergency Treatment Trials Network Six questions about the new network Robert Silbergleit, MD University of Michigan.
Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint
Hypertonic Saline – A Review of the Advantages and Disadvantages
Critical Appraisal of the European CAS Trials
Spinal Cord Ischemia during TEVAR
Plasma Protein Fraction
Pediatric Traumatic Brain Injury in 2012
Pre Hospital Recognition
Pediatric Traumatic Brain Injury in 2012
Steph Tilston Anaesthetic SpR Hurstwood Park Neurological Centre
INTRAVENOUS FLUIDS Batool Luay Basyouni
Presentation transcript:

The risk of Severe DIAR in Trauma Patients given HSD Eileen M. Bulger, MD Associate Professor of Surgery Co-PI Resuscitation Outcomes Consortium

Hypertonic Saline Dextran 7.5% saline/6% dextran-70, 250cc given as initial resuscitation fluid for patients with hypovolemic shock 7.5% saline/6% dextran-70, 250cc given as initial resuscitation fluid for patients with hypovolemic shock Approved in 14 European countries, Rescueflow, Biophausia Inc, Sweden Approved in 14 European countries, Rescueflow, Biophausia Inc, Sweden 8 previous clinical trials,meta-analysis demonstrates improved survival OR 1.47 and 2 fold increase in survival for patients with traumatic brain injury 1,2 8 previous clinical trials,meta-analysis demonstrates improved survival OR 1.47 and 2 fold increase in survival for patients with traumatic brain injury 1,2

Advantages of HSD Resuscitation 3 More rapid restoration of perfusion with small volume More rapid restoration of perfusion with small volume Improved cerebral perfusion while decreasing intracranial pressure Improved cerebral perfusion while decreasing intracranial pressure May alter the response of the immune system after injury: May alter the response of the immune system after injury: Decrease the risk of developing lung injury (ARDS) by inhibiting neutrophil and monocyte activation Decrease the risk of developing lung injury (ARDS) by inhibiting neutrophil and monocyte activation Reduce nosocomial infection by enhanced T cell function Reduce nosocomial infection by enhanced T cell function

Current & Proposed Trials Current trial at University of Washington Current trial at University of Washington Phase 2 trial, primary endpoint ARDS Phase 2 trial, primary endpoint ARDS Current enrollment 205pts, now on clinical hold Current enrollment 205pts, now on clinical hold Proposed ROC trial Proposed ROC trial Phase 3 trial, n=3018 Phase 3 trial, n=3018 Hypovolemic shock- 28 day survival Hypovolemic shock- 28 day survival Traumatic Brain Injury- Neurologic outcome Traumatic Brain Injury- Neurologic outcome

Resuscitation Outcomes Consortium NIH NIH NHLBI NHLBI NINDS NINDS CIHR CIHR US DOD US DOD Canadian DOD Canadian DOD

Limitations of Prior reports of DIAR Elective surgery, older population (mean age 60yrs), high rate w/ epidural or spinal anaesthesia Elective surgery, older population (mean age 60yrs), high rate w/ epidural or spinal anaesthesia Relies on comparison to historical controls from Relies on comparison to historical controls from No randomized controlled trial data available No randomized controlled trial data available

Risk of Severe DIAR in Trauma patients Experience with HSD Experience with HSD 900 pts in clinical trials, 20,100pts treated in Europe 900 pts in clinical trials, 20,100pts treated in Europe NO REPORTS OF DIAR NO REPORTS OF DIAR 0/21000, < 5/100,000 0/21000, < 5/100,000 Estimates based on Hypertonic hetastarch experience: 4-8/100, Estimates based on Hypertonic hetastarch experience: 4-8/100,

Comparison of Risk for Severe DIAR Trauma pts receiving HSD 0-4/100,000 Historical controls: Ljungstrom et al 6, /100,000 Historical controls: Ring et al 8 8/100,000 Promit premedication (20cc) Ljungstrom et al 9, /100,000 Annual anaphylaxis risk in community 11 21/100,000

Why Trauma patients may be protected? High circulating levels of catecholamines High circulating levels of catecholamines Rapid infusion of the solution may result in an excess of antigen in the blood and thus prevent the formation of immune complexes. Rapid infusion of the solution may result in an excess of antigen in the blood and thus prevent the formation of immune complexes.

Limitations of Promit Side effects: 1-57/100,000 9,10 Side effects: 1-57/100,000 9,10 Skin reactions Skin reactions Bradycardia +/- hypotension Bradycardia +/- hypotension Hypotension Hypotension HSD most effective as first fluid given HSD most effective as first fluid given Premedication may delay medic from other critical interventions Premedication may delay medic from other critical interventions Feasibility in prehospital or battlefield setting Feasibility in prehospital or battlefield setting Immuno-modulatory effects of Promit are unknown. May interfere with the effectiveness of HSD Immuno-modulatory effects of Promit are unknown. May interfere with the effectiveness of HSD

Summary Trauma patients receiving HSD at much lower risk of severe DIAR than previous reports. Trauma patients receiving HSD at much lower risk of severe DIAR than previous reports. To date no reports of DIAR with 21,000 patients receiving HSD. To date no reports of DIAR with 21,000 patients receiving HSD. There is no statistical difference between the estimated risk of severe DIAR for trauma patients receiving HSD and the projected risk with Promit pre-treatment for dextran infusion. There is no statistical difference between the estimated risk of severe DIAR for trauma patients receiving HSD and the projected risk with Promit pre-treatment for dextran infusion. We ask the committee to consider whether Promit premedication should be required in this circumstance. We ask the committee to consider whether Promit premedication should be required in this circumstance.

References 1. Wade C, Grady J, Kramer G. Efficacy of hypertonic saline dextran (HSD) in patients with traumatic hypotension: meta-analysis of individual patient data. Acta Anaesthesiol Scand Suppl 1997;110: Wade C, Grady J, Kramer G et al. Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension.1997 J Trauma 42:S Svensen C, Hypertonic Solutions: an update. ITACCS 2002, Schimetta W, Schochl H, Kroll W et al. Safety of hypertonic hyperoncotic solutions-a survey from Austria. Wien Klin Wochenschr 2002, 114: Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004, 139: Ljungstrom KG, Renck H, Standberg K et al. Reactions to dextran in Sweden Acta Chir Scand 149: , Hedin H, Ljungstrom K. Prevention of dextran anaphylaxis: ten years experience with hapten dextran. Int Arch Allergy Immunol 1997, 113: Ring J,Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitute. Lancet, Renck H, Ljungstrom K, Hedin H et al. Prevention of dextran-induced anaphylactic reactions by hapten inhibition. Acta Chir Scand 149: , Ljungstrom K, Willman B, Hedin H. Hapten inhibition of dextran anaphylaxis. Nine years of post-marketing surveillance of dextran 1. Ann Fr Anesth Reanim 12: , Yocum MW, Butterfield JH, Klein JS et al. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J allergy Clin Immunol, :